Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Lipomatous Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Mesenchymal Cell Neoplasm
Lipomatous Neoplasm

Cancer Family

Lipomatous Neoplasm

CI-CAN-00000216Explore in graph →

Non-malignant55 active trials1 approved drugs9 evidence items

NCIt: C4248
MeSH: D018205

Overview
Statistics
Survival
Genomics2
Variants & evidence9
Drugs2
Trials155
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (8)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–8 of 8 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Specificity of fusion genes in adipocytic tumors.
· Anticancer Res · 2010 · PMID 20332486 · validated civic_curation pubmed
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.
· J Clin Oncol · 2013 · PMID 23569312 · validated civic_curation pubmed
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.
· JAMA Oncol · 2016 · PMID 27124835 · validated civic_curation pubmed
Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma.
· J Clin Oncol · 2025 · PMID 39836945 · validated civic_curation pubmed
Fusion of the EWS and CHOP genes in myxoid liposarcoma.
· Oncogene · 1996 · PMID 8637704 · validated civic_curation pubmed
Cytogenetic findings in liposarcoma correlate with histopathologic subtypes.
· Cancer · 1992 · PMID 1568170 · validated civic_curation pubmed
The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice.
· Oncogene · 2000 · PMID 10828883 · validated civic_curation pubmed
FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma.

Showing 1–8 of 8 publications

· Clin Cancer Res · 2017 · PMID 28637688 · validated civic_curation pubmed